Clear Evidence Clarified

By Eric Lindenfeld


In 2009, the Supreme Court introduced the “clear evidence” standard for the defense of federal preemption in the pharmaceutical products liability context. For the next ten years, the contours of the standard were inconsistently applied by courts. The Supreme Court’s 2019 decision in Merck Sharp & Dohme Corp. v. Albrecht offers significant clarity to litigants. While certain issues remain unaddressed by the Court, it is clear that the newly stated rule dramatically limits defendants’ ability to assert the clear evidence standard. The rule is a positive step for consumer safety, provides a clear, administrable bright line, and is not unreasonably broad.

The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.

Back to Top